The "2023 Sustainability Bond Report" outlines Merck's use of $994 million in bond proceeds for projects focused on health access, environmental sustainability, and socioeconomic empowerment. The initiatives include reaching 33.6 million people through health equity projects, developing 3.7 million square feet of green building space, and achieving a 20% reduction in indoor water use in new projects.

The "MSD for Mothers Global Grants Program" aims to enhance maternal health by funding local projects. It has reached over 20.8 million women across 65 sites and trained 78,000 healthcare professionals. The program has directly benefited 4.7 million women. Despite these efforts, 800 women still die daily from preventable childbirth-related causes.

The "Merck Impact Report 2022/2023" emphasizes Merck's dedication to global health, environmental sustainability, and ethical practices. The report highlights that Merck has reached over 500 million people globally with health innovations, committed $1 billion in sustainability bonds, and reduced operational GHG emissions by 46% from a 2019 baseline. The company is on track to achieve 100% renewable energy use by 2025 and maintains greater than 99% pay equity. Additionally, Merck spent $3.2 billion with diverse suppliers, reflecting its efforts to foster a diverse workforce and improve access to healthcare.

The "Clinical Trials Infographic 2023" underscores the significance of diverse representation in clinical trials to ensure research findings are applicable across different demographic groups. Key data from the infographic include a total of 292,537 participants in clinical trials (FDA 2015-2019), with 76% identifying as White, 11% as Asian, and 7% as Black or African American. Additionally, 67% of participants are not Hispanic or Latino, while 20% are Hispanic or Latino. The infographic highlights that participation is voluntary, offers access to knowledgeable medical care, and supports the advancement of medical research.